Skip to Content

RAS Mutation Detection in Tumors

RAS Mutation Detection in Tumors

Indication:  

To detect activating point mutations in the KRAS and NRAS genes, which are commonly present in leukemias with monocytic differentiation (AML, CMML), and in solid tumors such as melanoma, lung cancer and colorectal carcinoma. Presence of KRAS mutations have been shown to confer resistance to anti-EGFR monoclonal antibodies.

Methodology:  

This test is performed by PCR-based Pyrosequencing of DNA to examine the mutation status of codons 12 and 13 in exon 2 and codon 61 in exon 3 of KRAS and NRAS.

Test Parameters:  

This assay can detect mutations present in codons 12, 13 and 61 of KRAS and NRAS. The sensitivity of the Pyrosequencing assay is 5-10% of variant sequence in the background of wild-type sequence.

Turnaround Time:

7-10 days

Sample Requirements:
10 mL peripheral blood, 2-5mL bone marrow aspirate, 5g purified DNA, or 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.
Please provide a copy of the corresponding pathology report.

CPT Codes:

81275, 81403, 81404

Additional charges may apply for tissue extraction.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center